scispace - formally typeset
Z

Z. H. An

Researcher at University of California, San Francisco

Publications -  22
Citations -  8752

Z. H. An is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Autophagy & Phosphorylation. The author has an hindex of 12, co-authored 22 publications receiving 7042 citations. Previous affiliations of Z. H. An include Shandong University & University of Texas Southwestern Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Daniel J. Klionsky, +2983 more
- 08 Feb 2021 - 
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Journal ArticleDOI

Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation

TL;DR: It is shown that Beclin 1, an essential autophagy and tumor suppressor protein, is a target of the protein kinase Akt, and Akt-mediated phosphorylation of BeClin 1 functions in Autophagy inhibition, oncogenesis, and the formation of an autophile-inhibitory BeclIn 1/14-3-3/vimentin intermediate filament complex.
Journal ArticleDOI

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

TL;DR: Signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR-tyrosine kinase inhibitors (TKIs) or antibodies are discussed.